RayKnowChina Research Map
Shortlist

ChangzhouSoochow University

Third Affiliated Hospital of Soochow University

常州市第一人民医院

Listed for 16 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Third Affiliated Hospital of Soochow University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌9 papers led
  3. Hepatocellular carcinoma肝细胞癌17 papers led
  4. Stomach cancer胃癌25 papers led1 open trial led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤2 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  8. Neuroblastoma神经母细胞瘤1 paper led
  9. Multiple myeloma多发性骨髓瘤3 papers led
  10. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led1 open trial led
  11. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  12. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  13. Behçet disease白塞病0 papers led
  14. IgA nephropathyIgA 肾病2 papers led
  15. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  16. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Hepatoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Changzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic disease
Departments in papersENT / head & neck surgery

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 9 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 3320242025: 332025

3 hospitals in Changzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyImaging & AI
Departments in papersRadiation oncologyMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led9
  1. Progenitor-exhausted T cell as prognostic indicator in esophageal squamous cell carcinoma: illuminating their key contribution to tumor immunity.2025Frontiers in immunologyFree full text
  2. Multimodal deep learning for predicting PD-L1 biomarker and clinical immunotherapy outcomes of esophageal cancer.2025Frontiers in immunologyFree full text
  3. m6A-modified circCREBBP enhances radiosensitivity of esophageal squamous cell carcinoma by reducing the stability of MYC through interaction with IGF2BP3.2025International journal of biological macromolecules
  4. Expression of Glutathione Peroxidase4 in Patients with Esophageal Squamous Carcinoma and Its Impact on the Radiosensitivity of Esophageal Squamous Carcinoma.2024Annals of clinical and laboratory science
  5. Predictive and Carcinogenic Roles of Necroptosis-Related miR-425-5p and miR-16-5p in Esophageal Squamous Cell Carcinoma.2024Annals of clinical and laboratory science
  6. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.2024Journal of cardiothoracic surgeryFree full text
  7. Transhiatal esophagectomy via mediastinoscopy versus sweet for T2 esophageal squamous cell carcinoma patients.2023Asian cardiovascular & thoracic annals
  8. Identification of Differentially Expressed Genes Related to the Lipid Metabolism of Esophageal Squamous Cell Carcinoma by Integrated Bioinformatics Analysis.2022Current oncology (Toronto, Ont.)Free full text
  9. Inhibition of BRD4 Suppresses the Growth of Esophageal Squamous Cell Carcinoma.2021Cancer investigation
All its trials on ClinicalTrials.gov, any status5
  1. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  3. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  5. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 17 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 7720242025: 662025

2 hospitals in Changzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led17
  1. TGF-β signaling orchestrates cancer-associated fibroblasts in the tumor microenvironment of human hepatocellular carcinoma: unveiling insights and clinical significance.2025BMC cancerFree full text
  2. Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.2025European journal of medical researchRCTFree full text
  3. Identification of MAGE-A10 specific T cell receptor promising in immunotherapy of hepatocellular carcinoma.2025International journal of biological macromolecules
  4. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  5. The ubiquitination degradation of KLF15 mediated by WSB2 promotes lipogenesis and progression of hepatocellular carcinoma via inhibiting PDLIM2 expression.2025Journal of gastroenterology and hepatology
  6. Multiparametric radiomic analysis of MRI for predicting satellite nodules and recurrence-free survival in patients with hepatocellular carcinoma.2025Magnetic resonance imaging
  7. Nodule-in-nodule architecture of hepatocellular carcinomas: enhancement patterns in the hepatobiliary phase and pathological features.2024Abdominal radiology (New York)
  8. CEMRI-Based Quantification of Intratumoral Heterogeneity for Predicting Aggressive Characteristics of Hepatocellular Carcinoma Using Habitat Analysis: Comparison and Combination of Deep Learning.2024Academic radiology
  9. Comprehensive Analysis of the Immunosuppressive Function of Regulatory T Cells in Human Hepatocellular Carcinoma Tissues.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  10. hsa_circ_0000518 stimulates the malignant progression of hepatocellular carcinoma via regulating ITGA5 to activate the Warburg effect.2024Cellular signalling
  11. Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production.2024Immunopharmacology and immunotoxicology
  12. LncRNA ZFAS1 regulates ATIC transcription and promotes the proliferation and migration of hepatocellular carcinoma through the PI3K/AKT signaling pathway.2024Journal of cancer research and clinical oncologyFree full text
  13. Prognostic impact of the high-sensitivity modified glasgow prognostic score on patients undergoing radical surgery for hepatocellular carcinoma : Authorship.2024Langenbeck's archives of surgery
  14. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.2023Abdominal radiology (New York)
  15. The role of AIM2 in human hepatocellular carcinoma and its clinical significance.2023Pathology, research and practice
  16. Prognostic values of tissue-resident CD8+T cells in human hepatocellular carcinoma and intrahepatic cholangiocarcinoma.2023World journal of surgical oncologyFree full text
  17. Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1).2021BioengineeredFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 25 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
25
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 3320232024: 3320242025: 662025

3 hospitals in Changzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06241469

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Soochow UniversityChangzhou

  2. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  4. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs
Departments in papersMedical oncologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led25
  1. Radiomics-based assessment of HER2 status and prognosis in gastric cancer: a retrospective dual-center CT study.2025Abdominal radiology (New York)
  2. Expression characteristics and biological functions of CGB5 gene in gastric cancer.2025Acta histochemica
  3. The role and mechanism of ARID1A in immunotherapy of gastric cancer.2025Clinical and experimental medicineFree full text
  4. Mechanism and role of ferroptosis in the development of gastric cancer.2025Clinical and experimental medicineFree full text
  5. circGAPVD1 inhibits the progression of gastric cancer through miR-4424/STK4 axis and encoding GAPVD1-137aa protein.2025International journal of biological macromolecules
  6. GPX8 as a potential prognostic marker in gastric and colorectal cancer.2025MedicineFree full text
  7. Sema3A Alleviates the Malignant Behaviors of Gastric Cancer Cells by Inhibiting NRP-1.2024Current molecular medicine
  8. Unraveling the immunogenic cell death pathways in gastric adenocarcinoma: A multi-omics study.2024Environmental toxicology
  9. Hypoxia promotes metastasis by relieving miR-598-3p-restricted glycolysis in gastric cancer.2024Journal of translational medicineFree full text
  10. Incremental value of PET primary lesion-based radiomics signature to conventional metabolic parameters and traditional risk factors for preoperative prediction of lymph node metastases in gastric cancer.2023Abdominal radiology (New York)
  11. Circulating tumor cells in gastric cancer: developments and clinical applications.2023Clinical and experimental medicine
  12. CD226 identifies functional CD8+T cells in the tumor microenvironment and predicts a better outcome for human gastric cancer.2023Frontiers in immunologyFree full text
  13. N6-methyladenosine demethylase FTO promotes growth and metastasis of gastric cancer via m6A modification of caveolin-1 and metabolic regulation of mitochondrial dynamics.2022Cell death & diseaseFree full text
  14. PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer.2022Current oncology (Toronto, Ont.)Free full text
  15. Association Between Single Nucleotide Polymorphisms of miRNAs and Gastric Cancer: A Scoping Review.2022Genetic testing and molecular biomarkers
  16. The Regulation between CD4+CXCR5+ Follicular Helper T (Tfh) Cells and CD19+CD24hiCD38hi Regulatory B (Breg) Cells in Gastric Cancer.2022Journal of immunology researchFree full text
  17. The expression and clinical significance of IQGAP3 in gastric cancer.2022Minerva gastroenterology
  18. Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients.2022Nuclear medicine communications
  19. Relationship between total lesion glycolysis of primary lesions based on 18F-FDG PET/CT and lymph node metastasis in gastric adenocarcinoma: a cross-sectional preliminary study.2022Nuclear medicine communications
  20. EMT (Epithelial-mesenchymal transition) in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures.2021Asian journal of surgery
  21. Diagnosis and treatment of gastric schwannoma.2021Asian journal of surgery
  22. IL-1R2 expression in human gastric cancer and its clinical significance.2021Bioscience reportsFree full text
  23. Value of Plasma Methylated SFRP2 in Prognosis of Gastric Cancer.2021Digestive diseases and sciences
  24. Knockdown of Long Non-coding RNA LINC00200 Inhibits Gastric Cancer Progression by Regulating miR-143-3p/SERPINE1 Axis.2021Digestive diseases and sciences
  25. The Prognostic Value of the Prognostic Nutritional Index (PNI) in Radically Resected Esophagogastric Junction Adenocarcinoma.2021Nutrition and cancer
All its trials on ClinicalTrials.gov, any status13
  1. Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical StudyNot yet recruitingNCT06241469Lead (inferred)Phase 2Start 2024-02
  2. Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical StudyStatus unknownNCT05721651Lead (inferred)Phase 2Start 2023-04
  3. Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric CancerStatus unknownNCT05513144Lead (inferred)Start 2021-12
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  5. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  6. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  8. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  9. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  10. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06
  11. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  12. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  13. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. MiR-22-3p targeting alpha-enolase 1 regulates the proliferation of retinoblastoma cells.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

10 hospitals in Changzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led2
  1. Carboxypeptidase Vitellogenic-Like Promotes the Proliferation and Metastasis of Osteosarcoma through the TGF-β/Smad Signaling Pathway.2023Annals of clinical and laboratory science
  2. RNF38 inhibits osteosarcoma cell proliferation by binding to CRY1.2021Biochemistry and cell biology = Biochimie et biologie cellulaire
Earlier papers (2016–2020)9
  1. Erythrocyte membrane protein band 4.1-like 3 inhibits osteosarcoma cell invasion through regulation of Snai1-induced epithelial-to-mesenchymal transition.2020Aging
  2. Wnt5a/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells.2020Oncology reports
  3. Huangqi Fuzheng decoction exerts antitumor activity by inhibiting cell growth and inducing cell death in osteosarcoma.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma.2019Oncology reports
  5. MicroRNA-520d-3p inhibits osteosarcoma progression by degradation of Akt1.2018European review for medical and pharmacological sciences
  6. Retrospective analysis of the effect of treatment of osteosarcoma complicated by pathological fracture by neoadjuvant chemotherapy combined with limb salvage surgery.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  7. Association between H19 polymorphisms and osteosarcoma risk.2017European review for medical and pharmacological sciences
  8. Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.2017Oncology reports
  9. Gene silencing of USP1 by lentivirus effectively inhibits proliferation and invasion of human osteosarcoma cells.2016International journal of oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Changzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Endoscopic Characteristics of Small-Bowel Gastrointestinal Stromal Tumors Detected During Single-Balloon Enteroscopy: A Retrospective Analysis.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Changzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

3 hospitals in Changzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
    Phase
    Phase 1
    Started
    2022-04
    Registry
    NCT05181501

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsStem cell transplantDiagnosis, MRD & risk

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06867991

    Age 12 years to Not stated (registered criteria)

    Led by Third Affiliated Hospital of Soochow University; 1 listed hospital as study siteChangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisRecruitingNCT06867991Lead sponsorPhase 3Start 2024-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Changzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Changzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Changzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Changzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Progresses in diagnosis and treatment of familial adenomatous polyposis].2022Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

常州市第一人民医院

Third Affiliated Hospital of Soochow University

常州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data